The Pontificia Universidad Javeriana is a private higher education institution founded in 1623. It is one of the oldest, most traditional, and prestigious Colombian universities, directed by the Society of Jesus, with its main facilities in Bogotá and a second campus in Cali. It is one of the 28 universities entrusted to the Society of Jesus in Latin America and one of 114 around the world. The Javeriana University in Bogotá has 18 schools comprising 61 departments and 181 academic programs catering to areas of knowledge, giving the university its multidisciplinary nature. It has 45 buildings in 445 acres . The Javeriana University in Cali offers 18 schools in four faculties. It is located in Pance in southern Cali and it is one of the most remarkable educational institution in the city. Its Law School recently got its high quality accreditation granted to it by Resolution 6808 August 6, 2010, of the Ministry of National Education. The campus in Cali has sectional divisions of the Bolsa de Valores de Colombia , Temple University's Fox School of Business, and others.The Javeriana University is one of the twelve universities in Colombia having a high quality institutional accreditation, granted to it for eight years by Resolution 1320 June 12, 2003, of the Ministry of National Education. The university has 21 undergraduate programs with high quality accreditation; other eight programs are in the more advanced accreditation process stages.In graduate programs, quality is acknowledged through the Qualified Registries. The university has 87 graduate programs with Qualified Registries and has presented other 29 to these processes. Wikipedia.
News Article | May 5, 2017
(PR NewsChannel) / May 5, 2017 / Atlanta, Georgia Gabriel Nassar, MD, FACOG, Obstetrician and Gynecologist with his own practice, and affiliated with Atlanta Medical Center and Grady Memorial Hospital, has been named a 2017 Top Doctor in Atlanta, Georgia. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Gabriel Nassar is a very experienced physician, who has been in practice for more than 54 years. His long and successful career in medicine started in 1962, when he graduated from the Faculty of Medicine at the Pontifical Xavierian University in Bogota, Columbia. This was followed by an internship at San Juan de Dios City Hospital. After moving to the United States, Dr. Nassar completed a residency and then fellowship at Emory University’s Crawford Long Hospital in Atlanta, Georgia. Dr. Nassar is certified by the American Board of Obstetrics and Gynecology, and with his wealth of experience to call upon he has become renowned as one of Atlanta’s foremost experts in the treatment of women’s fertility issues. He is also noted as an expert in the use of minimally invasive surgery, speeding up typical recovery times. Dr. Nassar has earned the coveted title of Fellow of the American Congress of Obstetricians and Gynecologists, and is noted for his patient centric focus as well as his clinical excellence. In addition to his clinical work, he serves as Assistant Professor of OB GYN at Morehouse School of Medicine in Atlanta, Georgia..His dedication and expertise honed over more than five decades makes Dr. Gabriel Nassar a very worthy winner of a 2017 Top Doctor Award. About Top Doctor Awards Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.
News Article | November 30, 2016
TORONTO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Dr. Patricio Stocker, President and CEO of PharmaCielo Ltd., announced the company has appointed a Medical Advisory Board (MAB) to provide guidance on the development of medicinal-grade cannabis oil extracts and related products appropriate for use by clinical practitioners. “Under the guidance of Dr. Delon Human, PharmaCielo Board of Directors member and Chair of the MAB, appointees will be able to provide significant input in the development of our medicinal-grade products through their ability to provide global expertise in the areas of healthcare policy, regulation, medical science and patient insights in addition to their clinical experience,” said Dr. Stocker. Dr. Human has assembled an experienced team of international medical clinicians whose expertise will be leveraged to provide guidance in the development of medicinal-grade cannabis oil based products, as well as international insight and understanding of worldwide healthcare policy and its implications for this emerging global industry. “The Medical Advisory Board will oversee PharmaCielo’s practices and processes, ensuring they are UN-aligned and performed ethically and according to Good Manufacturing and Good Medical Practice,” said Dr. Human. “During the April 2016 UN General Assembly Special Session on Drugs, the UN and its member states strongly endorsed the need to ensure the accessibility and availability of internationally controlled drugs for medical and scientific purposes, including substances such as cannabinoids. In developing a global framework, this should be promoted within national legal systems, while simultaneously preventing diversion, abuse and trafficking. PharmaCielo has the opportunity to develop the world’s finest quality, naturally grown, pharma-grade cannabis oils.” Four appointees to the MAB were introduced (full biographies are available at www.pharmacielo.com): Dr. Delon Human is the president and CEO of Health Diplomats, a health advisory and consulting practice, providing strategic and technical advice on global health issues to Fortune 500 companies in the pharmaceutical, food, tobacco, nicotine and medical device industries as well as NGOs, governments and foundations. He has acted as adviser to WHO Director-Generals and UN Secretary-General Ban Ki Moon. He is a published author and specializes in global health strategy, corporate and product transformation, harm reduction and health communication. Formerly, he served as the Secretary-General of the International Food and Beverage Alliance (IFBA), which brings together the top food companies in the world. From 1997 to 2005, Dr. Human served as secretary general of the World Medical Association (WMA), the global representative body for physicians. He was instrumental in the establishment of the World Health Professions Alliance, an alliance of the global representative bodies of physicians, nurses, pharmacists, dentists and physical therapists. Dr. Human qualified as a physician in South Africa and completed his postgraduate studies in family medicine and child health in South Africa and Oxford, England. He was a clinician for two decades, part of the pediatric endocrinology research unit at the John Radcliffe Hospital and was involved in the establishment of several medical centers, a hospital and emergency clinic in South Africa. His business studies (MBA) were completed at the Edinburgh Business School. A former chair of the World Medical Association, Dr. Anders Milton is a highly sought-after consultant within the healthcare sector and has served as president of the European Regional Network on HIV/AIDS (ERNA) and as president of the Swedish Red Cross among a number of other positions, including appointment by the Swedish government as chairman of a committee on Swedish HIV/AIDS policies and a member of the Catastrophe Commission formed following the December 2004 tsunami. Recently he led a select committee studying organ donation and transplantation. Previously, Dr. Milton served as president and CEO of the Swedish Medical Association. A director of several public and privately held companies and foundations, Dr. Milton originally studied economics before turning to medicine, and after graduating university as a medical doctor and PhD he served as a clinician at the Department of Nephrology at the University Hospital at Uppsala. Throughout his career he has been engaged in work in support of human rights, ethics of medical practice and safe health care, of which effective pharmacotherapy is an integral part. Dr. Gutiérrez is a neuroradiologist in private practice and Director of the Neuroradiology Division at Centro Avanzado de Diagnostíco Médico (CEDIMED) in Colombia. Previously, Dr. Gutiérrez served at the University of Texas Health Science Center in San Antonio, TX as Associate Professor of Radiology, Vice Chair of Clinical Operations, Medical Director and Director of the Clinical Trials Division at the Radiology Department. He was formerly Director of Medical Development, Diagnostic Imaging and Associate Director of Clinical Development, Diagnostic Imaging for Bayer Healthcare (formerly Berlex Laboratories) in Montville, NJ. Dr. Gutiérrez also served as a medical monitor with Novartis (formerly Ciba-Geigy Labs) in Medellin. Dr. Gutiérrez has been the recipient of several awards for his work, and has been the lead researcher, international researcher and co-investigator on numerous clinical trials. Regularly published, he has co-edited five medical books and authored or co-authored over 25 book chapters as well as 17 peer-reviewed articles and scores of abstracts and articles published in scientific research journals. Dr. Gutiérrez received a Doctorate in Medicine and Surgery from CES University in Medellin and Specialist in Clinical Radiology from Pontifical Xavierian University / San Ignacio Hospital in Bogota. He completed a research fellowship in Neuroradiology at Thomas Jefferson University / TJU Hospital in Philadelphia, PA and a visiting fellowship in Interventional Neuroradiology at the University of Miami / Jackson Memorial Hospital. Dr. Soto is Chairman of the Department of Radiology at Boston Medical Center and a Professor of Radiology at the Boston University School of Medicine. He has previously served as a general medical practitioner with the Hospital San Antonio de Prado in Colombia, section head of Body Imaging at University of San Vicente de Paúl Hospital, radiologist at CEDIMED in Medellin, assistant professor of Radiology at the University of Antioquia and was vice chairman of Boston Medical Center’s Department of Radiology for ten years. A native of Medellin with citizenship in both Colombia and the United States, Dr. Soto received his Doctor in Medicine and Surgery and Specialist in Diagnostic Radiology from CES University’s Health Sciences Institute in Medellin, and completed a Radiology Body Imaging Fellowship at Boston University Medical Center. Dr. Soto has received honors and awards from the Colombian Ministry of Education, Medellin Medicine Academy, Boston University Medical Center and numerous professional societies. An extensively published researcher, Dr. Soto is a member of the editorial boards of Radiology and Abdominal Imaging, has edited seven books and has published over 85 original research papers and more than 35 reviews, book chapters and case reports. PharmaCielo Ltd. (the “Company”) is a global company privately held and headquartered in Canada, with a focus on processing and supplying all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. The Company’s principal (and wholly-owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its Nursery and Propagation Centre located in Rionegro, Colombia. The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia’s ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, has built a compelling business plan focused on supplying the international marketplace. This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as demand for the Company’s products, currency exchange changes and risks, internal funding and the financial condition of the Company, product roll-out, competition, technological changes, and other commercial matters involving the Company, its products, and the markets in which the Company operates, as well as general economic conditions, which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. However, any further disclosures made on related subjects in subsequent reports should be consulted.
Novara C.,Polytechnic University of Turin |
Ruiz F.,Pontifical Xavierian University |
Milanese M.,Modelway Srl
IEEE Transactions on Automatic Control | Year: 2013
Optimal filters for nonlinear systems are in general difficult to derive or implement. The common approach is to use approximate solutions such as extended Kalman filters, ensemble filters or particle filters. However, no optimality properties can be guaranteed by these approximations, and even the stability of the estimation error cannot often be ensured. Another relevant issue is that, in most practical situations, the system whose variables have to be estimated is not known, and a two-step procedure is adopted, based on model identification from data and filter design from the identified model. However, the designed filter may display large performance deteriorations in the case of modeling errors. In this paper, a new approach overcoming these issues is proposed, allowing the design of optimal filters for nonlinear systems in both the cases of known and unknown system. The approach is based on the direct filter design from a set of data generated by the system. Either experimental or simulated data can be used for design. A bound on the number of data necessary to ensure a given filter accuracy is also provided, showing that the proposed approach is not affected by the curse of dimensionality. © 2012 IEEE.
Estela-Uribe J.F.,Pontifical Xavierian University
Fluid Phase Equilibria | Year: 2013
This is the first part of a series of two communications in which a Helmholtz energy model is developed and applied to the prediction of thermodynamic properties of non-polar fluids and their mixtures. In this first part, the application is concerned only with pure non-polar fluids.The Helmholtz energy model is based on previous work by the author and co-workers in which the Helmholtz energy of the fluid is represented as a contribution of two terms: one is an extended corresponding states model and the other is a correction term. In the case of single components, this correcting term is a function of temperature and density.In this study 18 fluids were considered, namely: the normal alkanes from ethane to octane, isobutane, ethylene, cyclohexane, benzene, toluene, nitrogen, carbon dioxide, carbon monoxide, oxygen and argon. Percentage absolute average deviations (AADs) were calculated with the following results: 0.175 for pρT data; 0.279 for saturation pressures; 0.168 and 0.324 for saturated-liquid and saturated-vapour densities, respectively; 1.364 and 1.563 for isochoric and isobaric heat capacities, respectively, and 0.638 for speeds of sound. This performance is, by and large, quite comparable with the demanded accuracy of modern technical Helmholtz energy models for fluids of industrial interest and practical applications in process design and simulation. © 2013 Elsevier B.V.
Estela-Uribe J.F.,Pontifical Xavierian University
Fluid Phase Equilibria | Year: 2013
This is the second part of a series of two communications in which a Helmholtz energy model is developed and applied to the prediction of thermodynamic properties of non-polar fluids and their mixtures. In this second part, the application is concerned only with mixtures of non-polar fluids.The Helmholtz energy model is based on previous work by the author and colleagues in which the Helmholtz energy of the fluid is represented as a contribution of two terms: one is an extended corresponding states model and the other is correction term. In the case of mixtures, this correcting term is mixing rule, in terms of local compositions, of a temperature- and density-dependent function. Local compositions are calculated with a coordination number model for square-well fluids.The mixtures that were considered were eight "primary" systems and 29 "secondary" systems of methane, ethane, propane, isobutane, n-butane, nitrogen, carbon dioxide, carbon monoxide, hydrogen and argon and a few ternary and quaternary systems. Percentage absolute average deviations (AADs) were calculated with the following results: 0.114 and 0.255 for pρT data of primary and secondary mixtures, respectively; 0.094 and 0.052 for pρT data of ternary and quaternary systems, respectively; 1.153 and 0.108 for isobaric heat capacities and speeds of sound of primary mixtures, respectively; 1.210 and 1.280 for bubble-point vapour pressures of primary and secondary mixtures, respectively; and absolute average deviations of 0.744cm3/mol and 288cm6/mol2 for second and third virial coefficients, respectively. This performance was found to be very satisfactory when compared with the expected accuracy of mixture Helmholtz energy models, i.e. that by Lemmon and Jacobsen, which is cited further ahead. © 2013 Elsevier B.V.
Estela-Uribe J.F.,Pontifical Xavierian University
Fluid Phase Equilibria | Year: 2013
In this work a Helmholtz energy mixture model that had been previously published by the author was applied to natural gases and the related multicomponent systems. The Helmholtz energy of the mixture is the sum of two terms: one is an extended corresponding states model and the other is a correction term that is mixing rule, in terms of local compositions, of a temperature- and density-dependent function. Local compositions are calculated with a coordination number model for square-well fluids.The systems of interest were ternary, quaternary, multicomponent systems and natural gases. Deviations were calculated for pρT data, speeds of sound, isobaric heat capacities, isobaric and isenthalpic enthalpy differences, saturated-liquid densities of liquefied natural gases and vapour pressures of ternary systems. Representative percentage average absolute deviations were: 0.060 in pρT data of pipeline-quality natural gases; 0.099 in pρT data of unusual-composition natural gases; 0.249 in pρT data of rich natural gases; 0.220 in speeds of sound; 1.150 in isobaric heat capacities; 0.146 in saturated-liquid densities of liquefied natural gases and 1.267 in vapour pressures of ternary systems. Those results met the international standards of accuracy in the prediction of natural gas thermodynamic properties and were also comparable with those obtained with the GERG-2004 equation of state. © 2013 Elsevier B.V.
Ulloa J.C.,Pontifical Xavierian University
Canadian journal of microbiology | Year: 2010
Porcine astrovirus (PAstV) has been poorly studied and has been associated mainly with gastroenteritis. Computational analysis has revealed the close relationship of PAstV with astroviruses of humans (HAstV) and cats (FAstV). In this study, 105 and 171 stool specimens were collected from piglets and children under 5 years of age, respectively, in different Colombian regions during a 1-year period. The stool samples were examined for astroviruses by ELISA and RT-PCR; 23.8% and 4% were found to be positive for PAstV and HAstV, respectively. Additional sequence analysis with partial sequences obtained from ORF2 identified at least 2 probable groups of PAstVs and possible recombination events between porcine and human astroviruses. This study provides preliminary evidence of the high presence of PAstVs in pigs and proposes the existence of multiple PAstV types that are evolutionarily closely related to HAstVs.
Estela-Uribe J.F.,Pontifical Xavierian University
Fluid Phase Equilibria | Year: 2010
In this work a Helmholtz energy model is applied to the prediction of thermodynamic properties of air, the related binary mixtures and the intervening pure components. The Helmholtz energy of the mixture is represented as two contributions: one from a proven accurate extended corresponding states model and the other is a correction term. The corresponding states model relies on pure-component shape factors relative to nitrogen and extension to mixtures with the van der Waals one-fluid mixture model with ordinary combining rules. The correction term is temperature-, density- and composition-dependent with the use of a theoretically consistent local composition model with a coordination number model derived from lattice gas theory. For air the obtained average absolute deviations in densities were 0.090 per cent, 0.15 per cent in speeds of sound, 0.28 per cent in bubble-point pressures and 0.30 per cent for dew-point pressures. For the three associated binary mixtures, the absolute average deviations in densities were within 0.14 per cent and 0.63 per cent for bubble-point pressures. For oxygen and argon, the absolute average deviations were within 0.07 per cent in densities, 0.45 per cent in VLE properties and 0.012 per cent in speeds of sound. © 2009 Elsevier B.V. All rights reserved.
Gempeler R. F.E.,Pontifical Xavierian University
Revista Colombiana de Anestesiologia | Year: 2015
This reflective article presents the current state of cardiopulmonary resuscitation (CPR) and reviews it from a bioethical standpoint. It starts with the ineffectiveness of CPR and the reasons why today it is a universally applied procedure, sometimes without taking into consideration the wishes or condition of the patient. Possible courses of action for the continuous improvement of cardiopulmonary resuscitation are proposed, especially from the humanistic point of view. Greater involvement of patients and their families in medical decisions, particularly in the planning of medical management rather than in the acute phase of the disease - as is the case for CPR - is encouraged. © 2014 Sociedad Colombiana de Anestesiología y Reanimación.
Rojas-Reyes M.X.,Pontifical Xavierian University
Cochrane database of systematic reviews (Online) | Year: 2012
Surfactant therapy is effective in improving the outcome of very preterm infants. Trials have studied a wide variety of surfactant preparations used either to prevent or treat respiratory distress syndrome (RDS). In animal models, prophylactic surfactant leads to more homogeneous distribution and less evidence of lung damage. However, administration requires intubation and treatment of infants who will not go on to develop RDS. This is of particular concern with the advent of improved approaches to providing continuous distending pressure, particularly in the form of nasal continuous positive airway pressure (CPAP). To compare the effect of prophylactic surfactant administration to surfactant treatment of established RDS in very preterm infants at risk of RDS. We updated the search of the Cochrane Central Register of Controlled Trials (The Cochrane Library), MEDLINE, EMBASE, CINAHL, and clinical trials.gov register in December 13, 2011. Randomized and quasi-randomized controlled trials that compared the effects of prophylactic surfactant administration to surfactant treatment of established RDS in preterm infants at risk of RDS. Data regarding clinical outcomes were extracted from the reports of the clinical trials by the reviewers. Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group. Eleven studies were identified that met inclusion criteria [nine without routine application of continuous positive air way pressure (CPAP) in the selective treatment group; two with routine application of CPAP in the selective treatment group]The meta-analysis of studies conducted prior to the routine application of CPAP demonstrated a decrease in the risk of air leak and neonatal mortality associated with prophylactic administration of surfactant. However, the analyses of studies that allowed for routine stabilization on CPAP demonstrated a decrease in the risk of chronic lung disease or death in infants stabilized on CPAP. When all studies were evaluated together, the benefits of prophylactic surfactant could no longer be demonstrated. Although the early trials of prophylactic surfactant administration to infants judged to be at risk of developing RDS compared to selective use of surfactant in infants with established RDS demonstrated a decreased risk of air leak and mortality, recent large trials that reflect current practice (including greater utilization of maternal steroids and routine post delivery stabilization on CPAP) do not support these differences and demonstrate less risk of chronic lung disease or death when using early stabilization on CPAP with selective surfactant administration to infants requiring intubation.